secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2026-05-13T12:05:18+00:00
Accession:  0001213900-26-055462
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Protara Therapeutics Reports Q1 2026 Results, Advances TARA-002 Programs in LMs and NMIBC
--------------------------------------------------------------------------------

- Cash and cash equivalents and investments of $177.4 million as of March 31, 2026, expected to fund operations into 2028.
- Net loss of $17.8 million ($0.31 per share) for Q1 2026, compared to $11.9 million loss in Q1 2025.
- Intends to submit BLA for TARA-002 in Lymphatic Malformations in second half of 2027 based on STARBORN-1 trial.
- Expects to complete enrollment of BCG-Unresponsive cohort in ADVANCED-2 trial and initiate ADVANCED-3 trial in BCG-Naïve patients in second half of 2026.
- Updated interim safety and durability data from STARBORN-1 to be presented at ISSVA World Congress in May 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/0001213900-26-055462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/ea0288581-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-055462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer